Now showing items 1-7 of 7
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
OBJECTIVE: Our objective was to estimate the effectiveness of disease-modifying drugs (DMDs) in delaying multiple sclerosis (MS) disability progression in relapsing-onset (R-onset) definite MS patients under "real-world" ...
Effect of copayments on drug use in the presence of annual payment limits
OBJECTIVE: To test the hypothesis that deductibles (copayment combined with annual limits on out-of-pocket payments) may reduce the effect of copayments on drug use for patients who expect to reach the annual limit, using ...
Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression: First estimates
Objective: To estimate the cost-effectiveness (CE) of interferon beta-1b (IFN(beta)-1b) in slowing disability progression in persons with relapsing-remitting multiple sclerosis (RRMS). Methods: Treatment program costs and ...